Trigr Therapeutics Inc., a private Irvine, Calif.-based cancer drug developer founded by industry veteran George Uy, is licensing global commercial rights to five early stage antibodies from South Korea's ABL Bio Corp. for $4.3 million up front and up to $500 million in milestones, plus potential royalties. Together, the companies expect to advance development of the immunomodulatory bispecific antibodies to investigational new drug filings in the U.S. beginning next year.